Stay updated on Pembrolizumab/Vibostolimab vs Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab vs Durvalumab in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab vs Durvalumab in Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.0%

- Check22 days agoChange DetectedA site-wide NIH notice announces a transition update and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.3%

- Check29 days agoChange DetectedThe footer now identifies the site as running revision v3.7.2 instead of v3.7.1.SummaryDifference0.0%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov site revision changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check42 days agoChange DetectedThe study record history continues to show the trial’s version list and the sections updated in each version.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision history updated: a new entry 'Revision: v3.7.0' has been added and an older entry 'Revision: v3.6.6' removed, reflecting the latest version in the study record history.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Vibostolimab vs Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab vs Durvalumab in Lung Cancer Clinical Trial page.